An unusual manifestation of post‐transplant lymphoproliferative disorder in the lip after pediatric heart transplantation

Chen, C.; Akanay-Diesel, S.; Schuster, Friedhelm R.; Klee, Doris; Schmidt, Klaus G.; Donner, Birgit

doi:10.1111/j.1399-3046.2012.01673.x

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To increase the number of cases, we combined our own data with data from the literature. From the literature, we identified a total of 61 reports on monomorphic B‐PTLD ( n = 34) , T‐PTLD ( n = 7) and polymorphic PTLD ( n = 20) with sinonasal and/or oro‐/nasopharyngeal manifestation. Therefore, including our cases, a total of 140 cases were evaluated (Table ).…”

Section: Resultsmentioning

confidence: 99%

Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation

et al. 2015

View full text Add to dashboard Cite

SummaryThe nasopharyngeal/oropharyngeal lymphatic tissues represent the anatomical site of Epstein-Barr virus (EBV) entry. Post-transplant lymphoproliferative disorders (PTLD) are often associated with EBV, but little is known about the characteristics of nasopharyngeal/oropharyngeal mass-forming PTLD. Retrospective evaluation of our own PTLD database (n = 79) and the PubMed â database (n = 61) has been performed. Sinonasal/oro-/nasopharyngeal lymphatic masses were early lesions (n = 54/140, 38.5%), polymorphic PTLD (n = 32/140, 23%), monomorphic B-PTLD (n = 47/140, 33.5%) and T-PTLD (n = 7/140, 5%). Onefourth of lesions manifested as masses in the Waldeyer's ring, and in two-thirds of cases, swelling of tonsils was related to manifestation of benign early lesions. Tonsil infiltration by polymorphic PTLD and monomorphic PTLD was present in one-third of cases. Extratonsillar masses were mainly monomorphic PTLD. Meta-analysis of our data in combination with previously published data revealed that lung transplantation and young patients are at a higher risk for earlier manifestation of monomorphic PTLD. Therapy is similar to PTLD therapy strategies, in general reduced immunosuppression and chemotherapy for polymorphic and monomorphic PTLD, and diagnostic and therapeutic surgical gross tumour resection of tonsillar/adenoid lesions. In summary, it is relevant for the clinical differential diagnosis that oro-/nasopharyngeal aggressive PTLD manifested in~30% as tonsillar masses and >90% at extratonsillar sites.

show abstract

Section: Resultsmentioning

confidence: 99%